Caplin Point Laboratories CAPLIPOINT
Branded generics in Latin America plus Caplin Steriles, a growing US injectables and ophthalmics business
Mapped in 1 theme: Pharmaceuticals.
Where Caplin Point Laboratories sits in the supply chain
Caplin Point Laboratories appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › Sterile injectables & fill-finish
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,694 | 1,937 | 2,187 |
| Net profit | 461 | 541 | 650 |
Latest-year revenue ₹2,187 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Net-cash, high-return and steady growth - FY26 profit ₹650 Cr
- US sterile pipeline building from Chennai plants with clean regulatory record
Risks
- Latin America currency and political risk
- US injectables pricing as more Indian capacity comes on
Common questions
What does Caplin Point Laboratories do?
Branded generics in Latin America plus Caplin Steriles, a growing US injectables and ophthalmics business.
Where does Caplin Point Laboratories sit in the supply chain?
Caplin Point Laboratories (NSE: CAPLIPOINT) is mapped in 1 supply-chain layer: Sterile injectables & fill-finish (Pharmaceuticals).
Who are Caplin Point Laboratories' peers?
In the Sterile injectables & fill-finish layer of Pharmaceuticals: Gland Pharma, Aurobindo Pharma, Piramal Pharma and Alembic Pharmaceuticals.
What is Caplin Point Laboratories' market cap and valuation?
As of 30 Oct 2026: market cap ₹17,696 Cr, P/E 26.6x, ROCE 24.2%, ROE 20.9%, dividend yield 0.34%.